Answers are grounded in this paper and cite their sources.
Inhibitors of c-jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer. This overview will highlight biological inhibitors such as JNK-interacting protein (JIP) as well as small molecule inhibitors from various structural classes including, aminopyrimidines and indazoles.
No takes yet. Share an insight, caveat, or question.
LoGrasso et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: